Company: RNAC
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0001453687-25-000060
Chunk: 50

Company: Cartesian Therapeutics, Inc.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 1
Chunk 50
---
 17/919,092 will expire on April 15, 2041, and a patent granted on U.S. Patent Application No. 18/292,670 will expire on July 28, 2042, barring any potential patent term adjustment or terminal disclaimers. These U.S. patent applications are directed to compositions of matter, and U.S. Patent Application No. 18/292,670 is also directed to methods of use. In addition, PCT/US2024/020251 was filed on March 15, 2024, a composition-of-matter and method-of-use PCT application, and any national stage application based on it will expire on March 15, 2044. Also, PCT/US2024/020815 was filed on March 20, 2024, a composition-of-matter and method-of-use PCT application, and any national stage applications based on it will expire on March 20, 2044. In addition, a patent granted on any of European patent application 20773688.5, AU 2020241428, CA 3199205, CN 202080020956.1, IN 202117036675, KR 2023-7034215, or MX/a/2021/011196 will expire March 2040 and a patent granted on European patent application 21789568.9 will expire April 2041. All of these patent applications are composition-of-matter applications.  In addition, we had two registered marks protecting our brand and prospective products both domestically and internationally. With respect to the legacy Selecta assets, as of December 31, 2024, we had (i) 102 issued patents worldwide, including 11 patents issued in the United States and 91 issued outside the United States, set to expire on various dates in 2032 through 2043, (ii) 65 patent applications pending worldwide, including 12 U.S. applications and 53 applications outside the United States and (iii) two registered marks. 

In addition to patent protection, we also rely on trade secrets, know-how, trademarks, confidential information, other proprietary information and continuing technological innovation to develop, strengthen and maintain our competitive position. We seek to protect and maintain the confidentiality of proprietary information to protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection. Although we take steps to protect our proprietary information and trade secrets, including